FY2024 EPS Estimate for Neumora Therapeutics Cut by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at William Blair reduced their FY2024 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company will earn ($1.63) per share for the year, down from their previous forecast of ($1.48). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07). During the same quarter last year, the business earned ($1.14) earnings per share.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Neumora Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.67.

Neumora Therapeutics Price Performance

Shares of NMRA opened at $11.69 on Friday. Neumora Therapeutics has a 1 year low of $8.33 and a 1 year high of $21.00. The company’s fifty day moving average is $13.07 and its two-hundred day moving average is $11.41.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD purchased a new stake in Neumora Therapeutics in the 1st quarter valued at approximately $10,354,000. Callan Capital LLC raised its holdings in shares of Neumora Therapeutics by 222.6% in the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after acquiring an additional 456,207 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Neumora Therapeutics by 79.5% in the second quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock valued at $1,099,000 after acquiring an additional 49,527 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after acquiring an additional 85,706 shares during the last quarter. Finally, Auour Investments LLC acquired a new stake in shares of Neumora Therapeutics during the third quarter valued at $3,302,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Insider Activity

In related news, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now directly owns 20,100 shares of the company’s stock, valued at approximately $342,303. This represents a 41.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the transaction, the insider now owns 339,205 shares of the company’s stock, valued at $4,006,011.05. This trade represents a 8.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 110,538 shares of company stock worth $1,390,513. Company insiders own 26.40% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.